ClinicalTrials.gg

Program

insulin degludec

Also written as “insulin degludec/insulin aspart”, “insulin degludec/liraglutide” and “Insulin degludec”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 5 companies.

Furthest: phase 4, since Sep 21, 2018105 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk1000 open or runningphase 4since Sep 21, 2018Jan 30, 2008none ahead
Tonghua Dongbao Pharmaceutical22 open or runningphase 3since Aug 14, 2024Jun 2, 2024none ahead
Gan & Lee Pharmaceuticals11 open or runningphase 1since Aug 18, 2025Aug 18, 2025none ahead
Sino Biopharmaceutical11 open or runningphase 3since Jul 5, 2021Jul 5, 2021none ahead
Sunshine Lake Pharma10 open or runningphase 3since Mar 6, 2023Mar 6, 2023none ahead

Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since May 31, 2011.

  1. May 3, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02762578, NCT02773368
  2. Jul 22, 2016Phase 1 study in HealthyNovo Nordisk · NCT02844790 · 24 enrolled · China
  3. Sep 15, 20162 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT02906917, NCT02911948
  4. Mar 10, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03078478 · 1,609 enrolled · United States, Canada, Denmark and more
  5. May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
  6. Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
  7. Nov 16, 2017Phase 3 study in Diabetes MellitusNovo Nordisk · NCT03377699 · 225 enrolled · Argentina, Australia, Austria and more
  8. Sep 21, 2018Phase 4 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT03687827 · 498 enrolled · United States, Canada, Poland and more
  9. Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
  10. Jul 5, 2021Sino Biopharmaceutical’s first study: phase 3 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04955834 · 344 planned · China
  11. Mar 6, 2023Sunshine Lake Pharma’s first study: phase 3 study in Diabetes MellitusNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05802862 · 414 enrolled · China
  12. Jun 2, 2024Tonghua Dongbao Pharmaceutical’s first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
  13. Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
  14. Aug 18, 2025Gan & Lee Pharmaceuticals’ first study: phase 1 study in Diabetes Mellitus, Type 2New to Gan & Lee PharmaceuticalsGan & Lee Pharmaceuticals · NCT07146347 · 14 planned · Germany

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07146347Diabetes Mellitus, Type 2 · Germany1RecruitingGan & Lee PharmaceuticalsApr 1, 202614
NCT06559722Diabetes Mellitus, Type 23Not yet recruitingTonghua Dongbao PharmaceuticalOct 2025510
NCT06449703Healthy · China1RecruitingTonghua Dongbao PharmaceuticalJun 16, 202444
NCT05802862Diabetes Mellitus · China3CompletedSunshine Lake PharmaAug 16, 2024414
NCT04955834Diabetes Mellitus, Type 2 · China3RecruitingSino BiopharmaceuticalDec 31, 2025344
NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedNovo NordiskJun 23, 2022588
NCT03687827Diabetes Mellitus, Type 2 · United States, Canada, Poland and more4CompletedNovo NordiskDec 20, 2019498
NCT03377699Diabetes Mellitus · Argentina, Australia, Austria and more3CompletedNovo NordiskDec 17, 2020225
NCT03292185Diabetes Mellitus · China1CompletedNovo NordiskJan 2, 201824
NCT03175120Diabetes Mellitus · China, Hong Kong3CompletedNovo NordiskMar 5, 2019453
NCT03172494Diabetes Mellitus · China3CompletedNovo NordiskJun 14, 2019720
NCT03078478Diabetes Mellitus · United States, Canada, Denmark and more3CompletedNovo NordiskFeb 13, 20191,609
NCT02911948Diabetes Mellitus · Japan3CompletedNovo NordiskNov 17, 2017210
NCT02906917Diabetes Mellitus · United States, Algeria, Czechia and more3CompletedNovo NordiskAug 31, 2017532
NCT02844790Healthy · China1CompletedNovo NordiskSep 26, 201624
NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more3CompletedNovo NordiskSep 26, 2017420
NCT02762578Diabetes Mellitus · China3CompletedNovo NordiskMay 19, 2017543
NCT02648217Diabetes Mellitus · Algeria, India, Lebanon and more3CompletedNovo NordiskSep 4, 2016263
NCT02607306Diabetes Mellitus · Japan3CompletedNovo NordiskDec 15, 2017819
NCT02536859Diabetes Mellitus · Germany1CompletedNovo NordiskApr 14, 201660
NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more3CompletedNovo NordiskOct 3, 20181,012
NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more3CompletedNovo NordiskOct 5, 2016506
NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more3CompletedNovo NordiskDec 23, 2015420
NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNovo NordiskApr 201531
NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico3CompletedNovo NordiskJan 11, 2016501
NCT02030600Diabetes Mellitus · United States, Puerto Rico3CompletedNovo NordiskDec 4, 2015721
NCT01959529Diabetes Mellitus · United States, Algeria, Argentina and more3CompletedNovo NordiskOct 16, 20167,637
NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more3CompletedNovo NordiskNov 4, 2014557
NCT01916174Diabetes Mellitus · Germany1CompletedNovo NordiskNov 201350
NCT01880736Diabetes Mellitus · Japan3CompletedNovo NordiskApr 2014458
NCT01868581Diabetes Mellitus · Germany1CompletedNovo NordiskAug 200858
NCT01868568Diabetes Mellitus · Germany1CompletedNovo NordiskAug 200855
NCT01868555Diabetes Mellitus · Japan1CompletedNovo NordiskFeb 200832
NCT01868529Diabetes Mellitus · Germany1CompletedNovo NordiskJun 200863
NCT01865331Diabetes Mellitus · Germany1CompletedNovo NordiskMar 200732
NCT01865318Diabetes Mellitus · Germany1CompletedNovo NordiskJan 200736
NCT01865305Diabetes Mellitus · Germany1CompletedNovo NordiskFeb 200759
NCT01865292Diabetes Mellitus · Germany1CompletedNovo NordiskNov 200640
NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more3CompletedNovo NordiskMay 15, 2014833
NCT01835431Diabetes Mellitus · United States, Belgium, Brazil and more3CompletedNovo NordiskNov 7, 2014362
NCT01814137Diabetes Mellitus · United States, Algeria, Germany and more3CompletedNovo NordiskMar 201440
NCT01773798Diabetes Mellitus · Austria1CompletedNovo NordiskAug 201333
NCT01713530Diabetes Mellitus · United States, Algeria, Austria and more3CompletedNovo NordiskJan 9, 2014274
NCT01704417Diabetes Mellitus · Germany1CompletedNovo NordiskMar 201340
NCT01680341Diabetes Mellitus · United States, Algeria, Germany and more3CompletedNovo NordiskAug 22, 2013272
NCT01676116Diabetes Mellitus · United States, Australia, France and more3CompletedNovo NordiskMar 11, 2014438
NCT01664247Diabetes Mellitus · United States, Canada, France and more3CompletedNovo NordiskDec 31, 2013346
NCT01618162Diabetes Mellitus · United States, Bulgaria, Canada and more3CompletedNovo NordiskOct 23, 2013435
NCT01623375Diabetes Mellitus · Germany1CompletedNovo NordiskAug 201218
NCT01590836Diabetes Mellitus · Germany1CompletedNovo NordiskJun 201222
NCT01570751Diabetes Mellitus · United States, Puerto Rico3CompletedNovo NordiskJan 2014145
NCT01569841Diabetes Mellitus · United States3CompletedNovo NordiskNov 201224
NCT01513590Diabetes Mellitus · Algeria, Bulgaria, Croatia and more3CompletedNovo NordiskNov 19, 2012394
NCT01513473Diabetes Mellitus · United States, Bulgaria, Finland and more3CompletedNovo NordiskJul 30, 2013350
NCT01467414Diabetes Mellitus · Germany1TerminatedNovo NordiskDec 20111
NCT01455142Diabetes Mellitus · Austria1CompletedNovo NordiskJan 201232
NCT01437592Diabetes Mellitus · China1CompletedNovo NordiskNov 22, 201124
NCT01392573Diabetes Mellitus · United States, Bulgaria, Denmark and more3CompletedNovo NordiskOct 1, 2012413
NCT01388361Diabetes Mellitus · United States, Austria, Belgium and more3CompletedNovo NordiskJul 2012413
NCT01365507Diabetes Mellitus · United States, Korea, Republic of, Malaysia and more3CompletedNovo NordiskApr 2012276

How it is read

Names in the registry

  • “insulin degludec”, 73 entries
  • “insulin degludec/insulin aspart”, 35 entries
  • “insulin degludec/liraglutide”, 17 entries
  • “Insulin degludec”, 4 entries
  • “Insulin degludec/liraglutide”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.